AstraZeneca’s Phase 3 CASPIAN Trial Fails to Meet Primary Endpoint
Eight Tips on How to Destress
AstraZeneca announced today that their phase 3 CASPIAN trial examining the efficacy of a second immunotherapy, tremelimumab, added to durvalumab (Imfinzi) in combination with a choice of standard-of-care (SoC) chemotherapies failed to meet its primary endpoint of demonstrating a statistically significant improvement in overall survival (OS) compared with durvalumab and SoC for patients with extensive-stage small cell lung cancer (ES-SCLC) treated in the firstline setting. It did, however, exhibit a sustained, clinically meaningful OS benefit for patients with ES-SCLC. Imfinzi, meanwhile, was granted a prority review by the FDA and had its Prescription Drug User Fee Act date set for the first quarter of this year. In dealing with stress, an indicator of high blood pressure when chronic, Idaho Falls magazine provided 8 tips on how to destress when feeling overwhelmed. In the tips, authors highlight the need for breathing deeply and going for a walk, 2 steps that can help guide users to safely relieve built-in stress. Additionally, diet and sleep play key roles in promoting cognitive function, which the researchers indicate can assist users in tackling issues with greater fervor. The role of technology was noted as a potential stress-inducer as well, citing the need to turn off one’s cell phone to limit distractions.